NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$339.0m

Last Updated

2021/05/15 23:41 UTC

Data Sources

Company Financials +

Executive Summary

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Biodesix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BDSX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: BDSX's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

-11.4%

BDSX

-2.0%

US Healthcare

-1.7%

US Market


1 Year Return

n/a

BDSX

39.3%

US Healthcare

50.8%

US Market

Return vs Industry: Insufficient data to determine how BDSX performed against the US Healthcare industry.

Return vs Market: Insufficient data to determine how BDSX performed against the US Market.


Shareholder returns

BDSXIndustryMarket
7 Day-11.4%-2.0%-1.7%
30 Day-34.1%4.1%-1.2%
90 Day-49.1%14.7%0.4%
1 Yearn/a41.1%39.3%53.3%50.8%
3 Yearn/a59.9%53.4%61.5%51.4%
5 Yearn/a108.8%93.2%125.9%100.7%

Long-Term Price Volatility Vs. Market

How volatile is Biodesix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biodesix undervalued compared to its fair value and its price relative to the market?

9.28x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BDSX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BDSX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BDSX is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: BDSX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BDSX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BDSX is overvalued based on its PB Ratio (9.3x) compared to the US Healthcare industry average (3.5x).


Future Growth

How is Biodesix forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

27.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BDSX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BDSX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BDSX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BDSX's revenue (7.5% per year) is forecast to grow slower than the US market (9% per year).

High Growth Revenue: BDSX's revenue (7.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BDSX is forecast to be unprofitable in 3 years.


Past Performance

How has Biodesix performed over the past 5 years?

13.7%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: BDSX is currently unprofitable.

Growing Profit Margin: BDSX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BDSX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare BDSX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BDSX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (59.7%).


Return on Equity

High ROE: BDSX has a negative Return on Equity (-78.52%), as it is currently unprofitable.


Financial Health

How is Biodesix's financial position?


Financial Position Analysis

Short Term Liabilities: BDSX's short term assets ($81.2M) exceed its short term liabilities ($16.1M).

Long Term Liabilities: BDSX's short term assets ($81.2M) exceed its long term liabilities ($62.9M).


Debt to Equity History and Analysis

Debt Level: BDSX's debt to equity ratio (90.7%) is considered high.

Reducing Debt: Insufficient data to determine if BDSX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BDSX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BDSX has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 17.2% each year.


Dividend

What is Biodesix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BDSX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BDSX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BDSX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BDSX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BDSX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Scott Hutton (48 yo)

1.33yrs

Tenure

US$1,583,534

Compensation

Mr. Scott Hutton serves as President, Chief Executive Officer and Director at Biodesix, Inc. since January 1, 2020. He served as Chief Operating Officer at Biodesix, Inc. since March 2018 until December 20...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD1.58M) is about average for companies of similar size in the US market ($USD1.74M).

Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BDSX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: BDSX's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: BDSX only recently listed within the past 12 months.


Top Shareholders

Company Information

Biodesix, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biodesix, Inc.
  • Ticker: BDSX
  • Exchange: NasdaqGM
  • Founded: 2005
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$338.986m
  • Shares outstanding: 26.86m
  • Website: https://www.biodesix.com

Number of Employees


Location

  • Biodesix, Inc.
  • 2970 Wilderness Place
  • Suite 100
  • Boulder
  • Colorado
  • 80301
  • United States

Listings


Biography

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tes...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 23:41
End of Day Share Price2021/05/14 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.